Plurimen tablets

Plurimen

  • Active Ingredient: Selegiline
  • 5 mg
Buy Now

What is Plurimen?

The active ingredient of Plurimen brand is selegiline. Selegiline prevents the breakdown of a chemical in your brain called dopamine (DO pa meen). Low levels of this chemical are associated with Parkinson's disease.

Used for

Plurimen is used to treat diseases such as: ADHD, Depression, Major Depressive Disorder, Parkinson's Disease.

Side Effect

Possible side effects of Plurimen include: tender, swollen glands in the neck; unusual tiredness or weakness; trouble concentrating; feeling sad or empty; fast or irregular pulse (continuing); shakiness and unsteady walk; body aches or pain.

How to Buy Plurimen capsules online?

To purchase Plurimen online - just click on the "Buy Now" button from the top and follow along with our store. Payment and Order takes a couple of minutes, and all measures are obvious. We do not take a medical prescription plus we have many methods of payment. With all the details of rapid delivery and confidentiality, you can read on the applicable pages on the links from the navigation menu.

Related Medications

Galopran

Galopran 40mg, 20mg

citalopram

More info

Aremis

Aremis 100mg, 50mg, 25mg

sertraline

More info

Bivien

Bivien 40mg, 20mg

citalopram

More info

Trant

Trant 100mg

trazodone

More info

How to store Plurimen

  • Keep all medicines out of the reach and sight of children.
  • Store in a cool, dry place, away from direct heat and light.

Pregnancy

Pregnancy Category C: No teratogenic effects were observed in a study of embryo-fetal development in Sprague-Dawley rats at oral doses of 4, 12, and 36 mg/kg or 4, 12 and 35 times the human therapeutic dose on a mg/m 2 basis. No teratogenic effects were observed in a study of embryo-fetal development in New Zealand White rabbits at oral doses of 5, 25, and 50 mg/kg or 10, 48, and 95 times the human therapeutic dose on a mg/m 2 basis; however, in this study, the number of litters produced at the two higher doses was less than recommended for assessing teratogenic potential. In the rat study, there was a decrease in fetal body weight at the highest dose tested. In the rabbit study, increases in total resorptions and % post-implantation loss, and a decrease in the number of live fetuses per dam occurred at the highest dose tested. In a peri- and postnatal development study in Sprague-Dawley rats (oral doses of 4, 16, and 64 mg/kg or 4, 15, and 62 times the human therapeutic dose on a mg/m 2 basis), an increase in the number of stillbirths and decreases in the number of pups per dam, pup survival, and pup body weight (at birth and throughout the lactation period) were observed at the two highest doses. At the highest dose tested, no pups born alive survived to Day 4 postpartum. Postnatal development at the highest dose tested in dams could not be evaluated because of the lack of surviving pups. The reproductive performance of the untreated offspring was not assessed.

There are no adequate and well-controlled studies in pregnant women. Plurimen should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

International Brand Names

Log on to ExpertConsult.com for a list of all international brand names.

Apo- Plurimen (New Zealand); Elegelin (Thailand); Julab (Hong Kong, Thailand); Julegil (Malaysia); Jumex (Austria, China, Hong Kong, Hungary, Indonesia, Israel, Italy, Korea, Malaysia, Philippines, Thailand); Jumexal (Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Switzerland, Taiwan); Kinline (Thailand); MAO-B (Korea); MAOtil (Germany); Movergan (Germany); Niar (Mexico); Otrasel (France); Plurimen (Spain); Procythol (Greece); Sedicel (Colombia); Sefmex (Hong Kong); Selegil (Colombia, Peru); Selegos (Hong Kong, Singapore); Selgene (Thailand); Selgin (India); Xilopar (Germany); Zelapar (Philippines)

Pharmacology and mechanism of action

Dopamine agonist. Plurimen has been known by many names. Plurimen hydrochloride is the official United States Pharmacopeia (USP) drug name, but most clinicians know it by the older name, l-deprenyl. (l-deprenyl is distinguished from its steroisomer d-deprenyl.) A related drug is rasagiline. Plurimen has been used in humans for treatment of Parkinson disease and occasionally for Alzheimer disease with the trade name Eldepryl. (Efficacy for Alzheimer disease has not been established.)

The veterinary formulation is approved for treatment of Cushing disease in dogs and canine cognitive dysfunction. The action of Plurimen is to inhibit monoamine oxidase (MAO) type B (and other MAOs at higher doses). The proposed mechanism of action is to inhibit the metabolism of dopamine in the CNS. The action for pituitary-dependent hyperadrenocorticism may be through increased dopamine levels in the brain, which decreases ACTH release, resulting in lower cortisol levels. Secondary effects are related to inhibition of the metabolism of phenylethylamine. (Phenylethylamine in laboratory animals produces amphetamine-like effects.) Two active metabolites are l-amphetamine and l-methamphetamine, but it is not known to what extent these contribute to pharmacologic effects. In horses, the metabolism to amphetamine-like metabolites is low.

PATIENT INFORMATION

Patients should be advised of the possible need to reduce levodopa dosage after the initiation of ELDEPRYL (Plurimen hcl) therapy.

Patients (or their families if the patient is incompetent) should be advised not to exceed the daily recommended dose of 10 mg. The risk of using higher daily doses of Plurimen should be explained, and a brief description of the 'cheese reaction' provided. Rare hypertensive reactions with Plurimen at recommended doses associated with dietary influences have been reported.

Consequently, it may be useful to inform patients (or their families) about the signs and symptoms associated with MAOI induced hypertensive reactions. In particular, patients should be urged to report, immediately, any severe headache or other atypical or unusual symptoms not previously experienced.

INFORMATION FOR PATIENTS

Patients should be advised of the possible need to reduce levodopa dosage after the initiation of Plurimen therapy.

Patients (or their families if the patient is incompetent) should be advised not to exceed the daily recommended dose of 10 mg. The risk of using higher daily doses of Plurimen should be explained, and a brief description of the ‘cheese reaction’ provided. Rare hypertensive reactions with Plurimen at recommended doses associated with dietary influences have been reported.

Consequently, it may be useful to inform patients (or their families) about the signs and symptoms associated with MAOI induced hypertensive reactions. In particular, patients should be urged to report, immediately, any severe headache or other atypical or unusual symptoms not previously experienced.

There have been reports of patients experiencing intense urges to gamble, increased sexual urges, and other intense urges, and the inability to control these urges while taking one or more of the medications that increase central dopaminergic tone, that are generally used for the treatment of Parkinson’s disease, including Plurimen. Although it is not proven that the medications caused these events, these urges were reported to have stopped in some cases when the dose was reduced or the medication was stopped. Prescribers should ask patients about the development of new or increased gambling urges, sexual urges or other urges while being treated with Plurimen. Patients should inform their physician if they experience new or increased gambling urges, increased sexual urges or other intense urges while taking Plurimen. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking Plurimen.

Contraindications

Plurimen is contraindicated in patients with a known hypersensitivity to this drug.

Plurimen is contraindicated for use with meper >Drug Interactions . )

12) Plurimen and Seizures

A handful of animal studies suggest that Plurimen may have potential in preventing or controlling seizures.

For example, Plurimen has been reported to prevent seizures in mice with epilepsy .

A similar effect has also been reported in a rat model of epilepsy .

Nonetheless, it goes without saying that studies in human patients would be needed to see if this effect holds up.

HOW SUPPLIED

ELDEPRYL (Plurimen hcl) capsules are available containing 5 mg of Plurimen hydrochloride. Each aqua blue capsule is band imprinted with the Somerset logo on the cap and "Eldepryl (Plurimen hcl) 5 mg" on the body.

They are available as:

NDC 39506-022-60 bottles of 60 capsules. NDC 39506-022-30 bottles of 300 capsules.

Store at controlled room temperature, 59° to 86°F (15° to 30°C).

Somerset Pharmaceuticals, Inc. Tampa, FL 33607. Literature issued July 1998. FDA Rev date: 2/15/2001


© Copyright 2017-2020 - rootsdentclinic.com - We Care About You!

Sitemap